←
Anand Ganesan993 posts
Anand Ganesan avatar

Anand Ganesan

@Vortexium32

Director of Cardiac Electrophysiology,Flinders Medical Centre | Head, Cardiac Signals Analysis Lab| Professor of Medicine, Flinders University, Australia

◷ Joined June 2014▧ 30 Photos and videos
Henry Han avatar
⟳ Anand Ganesan retweeted
Henry Han@HanCardiomd·Oct 28

LBB Area Pacing vs RV Pacing for AV Block and Preserved Left Ventricular Function: The #LEAP-Block Trial 📍499 patients with #LVEF ≥50% randomized to LBBAP vs #RVP across 14 Chinese hospitals. 📍 Primary endpoint: 2.4% vs 12.5% favoring #LBBAP (P=0.003). 📍 HF events: 3.4% vs 11.3% with LBBAP vs RVP. 📍 LBBAP ⬇️ the 24-month primary endpoint risk (HR 0.37, 95% CI 0.19–0.73), with no significant differences in mortality or device complications. #LEAPBlock #Cardiology #HeartFailure #Pacing jamanetwork.com/journals/jam… @JAMACardio #JAMA

Post attachmentPost attachmentPost attachmentPost attachment
Roderick Tung avatar
⟳ Anand Ganesan retweeted
Roderick Tung@DrRoderickTung·Oct 29

It is hard to find an indication to implant pacemakers in the RV apex.

LBB Area Pacing vs RV Pacing for AV Block and Preserved Left Ventricular Function: The #LEAP-Block Trial 📍499 patients with #LVEF ≥50% randomized to LBBAP vs #RVP across 14 Chinese hospitals. 📍 Primary endpoint: 2.4% vs 12.5% favoring #LBBAP (P=0.003). 📍 HF events: 3.4% vs 11.3% with LBBAP vs RVP. 📍 LBBAP ⬇️ the 24-month primary endpoint risk (HR 0.37, 95% CI 0.19–0.73), with no significant differences in mortality or device complications. #LEAPBlock #Cardiology #HeartFailure #Pacing jamanetwork.com/journals/jam… @JAMACardio #JAMA

Post attachmentPost attachmentPost attachmentPost attachment
Deep Chandh Raja avatar
⟳ Anand Ganesan retweeted
Deep Chandh Raja@DCR_Dr·Oct 1

On #WorldHeartDay, Chennai Heart Rhythm Trust (CHRT) conducted a cardiac health awareness drive and provided free health check-up packages for Chennai’s sanitary workers. Deeply heart-warming as a founding member to give back to those who keep our city running every day. ❤️🩺 Heartfelt thanks to Rotarians Prabhakar, Marshall, and Soundararajan (Rotary Mogappair) and CHRT Secretary Renuga for organizing this wonderful initiative! HeartHealth #CHRT #Chennai #Rotary

Post attachmentPost attachment
darius chapman avatar
⟳ Anand Ganesan retweeted
darius chapman@DariusChapman·Sep 8

We will unlock true AF mechanisms in the next few years. Maybe sooner. AF is fundamentally a problem of nonlinear, multiscale dynamics. The concept of 10k agents swarming together is impossible to imagine.

We’re sharing a solution to the Navier-Stokes Millennium Prize Problem, one of the deepest problems at the frontier of mathematics. The proof was produced by a group of agents, using an OpenAI next-generation model significantly more capable than GPT-6 Astra. The problem concerns whether the description of smooth three-dimensional fluid motion modeled by the Navier-Stokes equations can break down. It has remained unresolved for roughly 90 years.

Post attachment
darius chapman avatar
⟳ Anand Ganesan retweeted
darius chapman@DariusChapman·Sep 3

It’s all just topology. Topology, topology, topology, topology, Topology, topology, topology, topology, Topology, topology, topology, topology, Topology, topology, topology, topology.. Please don’t forget this. It’s really important.

Double figure-of-eight reentry during atrial tachycardia using 4 critical boundaries: A unique topological finding #OpenAccess heartrhythmjournal.com/artic…

Post attachment
C. Michael Gibson MD avatar
⟳ Anand Ganesan retweeted
C. Michael Gibson MD@CMichaelGibson·Aug 28

Dr. Joseph Selvanayagam and Dr. C. Michael Gibson discuss the CMR GUIDE trial: Scar-guided ICD implantation did not significantly reduce the primary composite endpoint of SCD/HSVA in patients with LVEF 36-50%. Watch video here: clinicaltrialresults.org/wp-…

11:02
Prof Joseph Selvanayagam DPhil FESC avatar
⟳ Anand Ganesan retweeted
Prof Joseph Selvanayagam DPhil FESC@josephselvacmr·Aug 29

It has been an immense privilege to lead this trial, and report on it at @escardio congress. All clinical trials are hard, investigator initiated trials even more so. Thank you to all investigators, trial staff, steering committee, DSMB, CEC and DDC members, and most of all patients and families who took part in the trial

🫀 CMR-GUIDE @ #ESCCongress2026, published in JAMA. 353 pts, LVEF 36–50% + #whyCMR scar, randomized to ICD vs loop recorder. ▪️ Primary endpoint neutral: HR 0.76 (0.37–1.66) ▪️ SCD lower with ICD: 1.7% vs 5.8% ▪️ Prespecified subgroup: benefit in patients <70 @SCMRorg

Post attachment
JAMA avatar
⟳ Anand Ganesan retweeted
JAMA@JAMA_current·Aug 28

📊 Research Summary: In patients with left ventricular ejection fraction of 36% to 50% and myocardial scar on #CardiovascularMagneticResonance, implantable cardioverter-defibrillator therapy lowered sudden cardiac death vs an implantable loop recorder, supporting further study of scar-guided device selection. #ESCCongress ja.ma/4hY8PZZ

JAMA avatar
⟳ Anand Ganesan retweeted
JAMA@JAMA_current·Aug 28

💬 Editorial by Sana Al-Khatib, MD, MHS: Current implantable cardioverter-defibrillator recommendations for primary prevention are based on left ventricular ejection fraction of 35% or less, yet many individuals who experience sudden cardiac arrest do not have marked left ventricular dysfunction. Cardiovascular magnetic resonance with late gadolinium enhancement may help identify higher-risk patients with left ventricular ejection fraction >35%, but randomized clinical trial evidence is still needed to guide practice. #ESCCongress ja.ma/46rkWHO

Anand Ganesan avatar
Anand Ganesan@Vortexium32·Aug 28

Nuanced message about CMR GUIDE - this was very tough trial to do and execute. The trial's primary endpoint wasn't positive - but it still has incredibly important signals about decreasing SCD, and role of ICD therapy in younger pts that we as EPs should think about

💬 Editorial by Sana Al-Khatib, MD, MHS: Left ventricular ejection fraction alone may not adequately identify patients at risk of sudden cardiac death, and cardiovascular magnetic resonance may refine risk assessment in those w/ left ventricular ejection fraction >35%. 🔗 ja.ma/4cjTyPw #ESCCongress @escardio

Post attachment
JAMA avatar
⟳ Anand Ganesan retweeted
JAMA@JAMA_current·Aug 28

🧵 Presented at #ESCCongress: Among patients with ischemic or nonischemic cardiomyopathy, left ventricular ejection fraction of 36% to 50%, and myocardial scar on #CardiovascularMagneticResonance, implantation of an implantable cardioverter-defibrillator did not significantly reduce sudden cardiac death or hemodynamically significant ventricular arrhythmia vs an implantable loop recorder. Rates of all-cause mortality, cardiovascular mortality, and heart failure–related hospitalization were also similar between groups. ja.ma/4xClJl2 @escardio

Post attachment
Anand Ganesan avatar
Anand Ganesan@Vortexium32·Aug 28

Really important to have nuanced messaging about these results.. #ESCCongress

#CMRGUIDE at #ESCCongress Should myocardial SCAR—not just EF—help determine who gets a primary-prevention ICD? Patients with: ➡️ LVEF 36–50% ➡️ Ischemic or nonischemic cardiomyopathy ➡️ Scar/fibrosis on CMR Randomized 353 pt, impacted by COVID, 82% Men ⏱️6.3 y ICD vs implantable loop recorder Primary Endpoint= SCD or hemodynamically significant ventricular arrhythmia 🌟RESULTS: Primary: SCD or hemodynamically significant ventricular arrhythmia ➡️ HR 0.76 (95% CI 0.37–1.58), P=.47 ❌ Sudden cardiac death alone: ➡️ HR 0.26 (0.07–0.95), P=.04 All-cause mortality: ➡️ HR 0.91 (0.49–1.71), P=.78 🫀 CMR-guided ICD implantation did not reduce the primary composite endpoint. The reduction in SCD is intriguing, but as a secondary endpoint in a negative trial it should be interpreted cautiously. CMR scar alone does not yet appear sufficient to expand ICD indications beyond current EF-based criteria. 📄 jamanetwork.com/journals/jam… @JAMA_current #WhyCMR #CardioTwitter #EPeeps #HeartFailure

Post attachmentPost attachmentPost attachmentPost attachment